pathway. In adult intestine, it is well established that the canonical Wnt signaling plays complementary roles in physiology and pathology: in health, it maintains crypt stem cell compartments, but, when activated by mutation, it is the cause of colon cancer. In this review, we discuss the canonical Wnt signaling pathway and its activating mechanisms in colorectal cancer (CRC). We will highlight the common Wnt pathwayassociated mutations identified in CRC and will further review the current therapeutic agents targeting Wnt signaling regarding their perspectives and challenges.
Wnt Signaling Pathway
Wnt signaling controls the level of the key modulator ␤-catenin for signal transduction through processes involving phosphorylation and ubiquitin-mediated degradation. This is regulated by the cytoplasmic ␤-catenin destruction complex, which consists of the core proteins AXIN, adenomatous polyposis coli (APC), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3). In the absence of Wnt, ␤-catenin is phosphorylated by CK1 and GSK3 in the complex, which is followed by recruitment of the E3 ligase ␤-TrCP to the complex for ubiquitination and subsequent proteasomal degradation ( Fig. 1) (1, 60, 72) . Upon Wnt ligand engagement to the receptors Frizzled (FZD) and low-density lipoprotein-related protein 5/6 (LRP5/6), the ␤-catenin destruction complex is recruited to the membrane, whereas ␤-TrCP is dissociated from the complex (71) . This is achieved by a scaffold protein Dishevelled (DVL) in the cytosol that transduces extracellular Wnt signals from receptors to downstream effectors (38) . DVL has the ability to bind to FZD receptor and AXIN protein via its PDZ and DIX domain, respectively, thus facilitating the interaction between the AXIN complex and the Wnt receptors. The DVL-AXIN interaction has been reported to inhibit the destruction complex by interfering with AXIN oligomerization via the DIX domain, whereas DVL polymerization is also believed to enhance Wnt receptor signalosomes (31, 98) . As a consequence, the complex-bound ␤-catenin is no longer ubiquitinated or degraded, leading to complex saturation and inhibition. This results in accumulation of free ␤-catenin in the cytoplasm and its subsequent nuclear translocation. In the nucleus, ␤-catenin displaces the repressor Groucho from T cell factor (TCF)/lymphoid enhancer-binding factor (LEF) transcription factors. ␤-Catenin/TCF/LEF, together with other coactivators, form an active transcriptional complex, leading to the expression of Wnt target genes (10, 81) .
In 2007, the Clevers laboratory first identified the Lgr5 as an intestinal stem cell marker via transcriptomic analysis of Wnt/ TCF targets (6) . Subsequent studies demonstrated that LGR5 and its homologs mediate Wnt/␤-catenin signaling via Rspondin (17, 42) . Structural analysis of the receptor complex Wnt ligands are palmitoylated by the acyltransferase porcupine in the endoplasmic reticulum and transported to the Golgi complex. The transmembrane protein Wntless facilitates the subsequent transfer of Wnt ligands to the plasma membrane for secretion. ␤-Catenin, the key effector of Wnt signaling, will be constantly degraded by the destruction complex in the absence of Wnt. Casein kinase 1 (CK1) and glycogen synthase kinase 3␤ (GSK3␤) in the complex phosphorylate ␤-catenin, which is then recognized by the E3-ligase ␤-TrCP for ubiquitination and proteosomal degradation. Upon Wnt ligand engagement of the Frizzled and low-density lipoprotein-related protein (LRP) receptors, the destruction complex will be inhibited, and the free cytosolic ␤-catenin will be translocated to the nucleus. Within the nucleus, ␤-catenin binds to the T cell factor (TCF) transcription factor together with other coactivators such as cAMP-response element-binding proteinbinding protein (CBP) and p300 to regulate Wnt target gene transcription. The membrane-bound E3 ligases RNF43/ZNRF3 are Wnt negative feedback targets that will suppress Wnt signaling by removing Frizzled receptors from the cell surface and neutralizing the Wnt agonist R-spondin/leucinerich repeat-containing G protein-coupled receptor (LGR) complex formation. Mutations in different Wnt signaling components (represented with red arrows) are frequently observed in colorectal cancers and have been found to cause pathway deregulation and tumorigenesis. Inhibitors targeting Wnt signaling at different cellular levels of the cascade are summarized in green boxes. LEF, lymphoid enhancer-binding factor; IWP, inhibitor of Wnt production; APC, adenomatous polyposis coli; TNK, tankyrase; DVL, Dishevelled.
further revealed the interaction between LGR5, R-spondin, and the E3 ubiquitin ligases RING finger 43 (RNF43) and zinc and RING finger 3 (ZNRF3) (15, 90) . RNF43 and ZNRF3 are two transmembrane E3 ligases that inhibit Wnt signaling through binding and removing the Wnt receptors from the cell surface (48, 62) . It is believed that R-spondin potentiates Wnt signaling by forming a complex with LGR5 and RNF43/ZNRF3 to neutralize the Wnt negative feedback activity (18) . This has added further complexity to the Wnt/␤-catenin signaling regulation at the receptor level.
Wnt-Activating Mechanism in CRC
Wnt signaling is activated at the bottom of the intestinal crypts, which is crucial for stem cell maintenance and tissue homeostasis. Aberrant Wnt activation is frequently observed in human cancers, especially in CRC (12) . Human CRCs can be broadly classified into two major categories based on their molecular profiles: nonhypermutated microsatellite stable (MSS) CRCs and hypermutated microsatellite instability (MSI) cancers. MSS CRCs constitute the vast majority, where loss of the tumor suppressor APC is the early event to initiate adenoma formation (85) . Subsequent cancer progression requires stepwise accumulation of other mutations, such as in KRAS, PI3K, TGF-␤, p53, and/or SMAD4, which is known as the multistep somatic evolution model, the "Vogelgram" (30) . On the other hand, around 10 -15% of CRCs are caused by defective DNA mismatch repair (MMR) machinery that is often associated with MLH1 hypermethylation (12, 54, 113, 119) . These are characterized by the presence of insertions or deletions of nucleotides in microsatellite repeat regions widespread across the genome, hence their name as MSI tumors (54, 113).
The Wnt signaling pathway is aberrantly upregulated in both MSS and MSI CRCs (12) . Inactivating mutations of the negative regulator APC constitute the principal mechanism by which the Wnt pathway is activated in MSS CRCs. In MSI tumors, MMR defects result in high mutation rates in the entire genome, which is known as the hypermutation phenotype. As a consequence, frequent mutations are observed in multiple oncogenes and tumor suppressor genes, including Wnt pathway components such as APC, ␤-catenin, and/or AXIN2 (12) . In addition, epigenetic silencing of Wnt inhibitors by DNA hypermethylation has also been suggested as another common mechanism to activate the Wnt pathway. Indeed, several studies have reported epigenetic silencing of negative regulators of Wnt signaling, including the extracellular Wnt inhibitors SFRP1-5, WIF1, DKK1, and DKK3 (92, 93, 104, 107, 111, 120) , as well as the destruction complex proteins APC and AXIN2 (27, 34, 61, 83, 84, 104) . The high mutation rate of Wnt pathway components observed in human CRCs highlights the promise of Wnt signaling as a therapeutic target (12) . We discuss below the commonly observed mutations and the mechanisms by which they act in human CRCs.
Loss-of-Function Mutations
APC is a multifunctional tumor suppressor. It is a large scaffold protein that consists of multiple binding domains for various cellular functions, including WNT signal regulation, cell adhesion, and chromosomal segregation during mitosis (32, 79) . Mice with Apc mutations will develop adenomas in the intestine attributable to hyperactivation of Wnt (39) . Functional loss of APC results in constitutive activation of Wnt signaling and in chromosomal instability in human colorectal adenocarcinomas (80) . Germ-line mutations of the APC gene cause familial adenomatous polyposis (FAP) syndromes characterized by the presence of multiple polyps in the colon and predisposition to CRC development (29) . Mutations in different regions of the gene result in different degrees of polyposis. Two mutation hotspots at codons 1,061 and 1,309 have been identified that result in high polyposis penetrance (36) . In most cases of sporadic CRCs, APC mutations are frequently clustered between codons 1,309 and 1,450 (29) . The majority of APC mutations are frameshift and nonsense mutations, which cause premature protein truncation. Biallelic loss of APC is achieved through second loss-of-heterozygosity mutations (which are somatic rather than germ line). APC protein truncation is believed to activate Wnt/␤-catenin signaling through abrogation of destruction complex-mediated ␤-catenin ubiquitination (64) .
AXIN1 and AXIN2 are negative Wnt regulators and tumor suppressors that are found mutated in sporadic CRCs and also some familial cancer syndromes (97) . There are three germline mutations reported in AXIN2: two result in premature stop codons in exon 7 (65, 77) , whereas the other is a missense mutation in exon 5 (94) . These lead to genetic predisposition to CRC development and tooth agenesis. Several studies have described somatic mutations of AXIN2 in MSI CRCs, the majority of which are also localized in exon 7 (21, 74, 114) . In addition to mutations, epigenetic silencing of AXIN2 has also been reported, mostly in MSI CRCs (61) . Although no germline mutation of AXIN1 has been found in CRCs, several studies have reported AXIN1 somatic mutations (56, 103). AXIN is the scaffold protein in the destruction complex that mediates ␤-catenin ubiquitination and degradation. AXIN2 is also a well-known downstream Wnt target, which provides negative feedback upon Wnt activation. Loss of AXIN is believed to activate the Wnt pathway through disruption of the ␤-catenin destruction complex and the Wnt negative feedback mechanism. Further investigation is needed to define the functional and clinical difference between AXIN1 and AXIN2 mutations.
WTX (also known as FAM123B or adenomatous polyposis coli membrane recruitment 1, AMER1), is an X-linked gene mutated in Wilms tumors. In 2007, the Moon laboratory identified WTX as a component of the destruction complex that negatively regulates Wnt signaling by promoting ␤-catenin ubiquitination and degradation (76) . However, a more recent study showed that WTX could be a Wnt activator by promoting Wnt-induced LRP6 phosphorylation (112) , postulating a complex dual positive and negative role of WTX in Wnt signaling. In patients, truncating mutations of WTX are frequently observed in kidney and CRCs. More recent sequencing data show high mutation rates in CRCs, preferentially in MSI cases (12) . Further characterization of the role of WTX in the Wnt signaling pathway and CRCs will aid understanding of its clinical significance.
RNF43 and its homolog ZNRF3 have been recently identified as negative Wnt regulators by promoting FZD receptor turnover (48, 62). In mouse intestine, depletion of both RNF43 and ZNRF3 results in expansion and proliferation of the stem cell/Paneth cell compartment (62) . Recently, whole-exome sequencing of human CRCs identified a large number of somatic mutations in RNF43, with the majority associated with MSI cases (40) . RNF43 and ZNRF3 are expressed at the bottom of intestinal crypts to negatively regulate Wnt signaling by controlling Wnt receptor levels (62) . Loss of function mutations of RNF43 will lead to a failure of Wnt receptor removal in the crypt, thus activating Wnt signaling by increased sensitivity to the Wnt ligands from the surrounding niche. Such receptor-associated mutations are exogenous Wnt dependent, making it desirable for treatment with Wnt inhibitors targeting Wnt ligands/receptors.
Activating Mutations
The CTNNB1 gene encodes for ␤-catenin, the key transcription modulator of the Wnt signaling pathway. ␤-Catenin is also a subunit of cadherin protein complexes that play essential roles in coordinating cell-cell adhesion. Hotspot mutations within CTNNB1 that affect the regulatory NH 2 -terminal serine/ threonine residues, such as S45F and T41A, are found in MSI CRCs (82) . It is well characterized that ␤-catenin is first phosphorylated by CK1 at ser45, followed by GSK3␤-mediated phosphorylation at ser33, ser37, and thr41 within the destruction complex (72) . Activating point mutations at these amino acid residues will prevent ␤-catenin from being phosphorylated, thereby blocking the subsequent ␤-TrCP-mediated ubiquitination and degradation.
R-spondin proteins (RSPO1-4) are Wnt agonists that enhance Wnt signaling via engagement with the LGR and FZD receptors in the presence of Wnt ligands (17, 42) . Overexpression of RSPO1 in mouse intestine results in hyperproliferation and expansion of the crypts (58) . Exome sequencing data from a large cohort of patients have identified two recurrent gene fusions in CRCs, RSPO2-EIF3E (eukaryotic translation initiation factor 3) and RSPO3-PTPRK (receptor-type tyrosineprotein phosphatase ) that can potentiate Wnt signaling (100). Interestingly, these fusions were found in non-APC-mutated CRCs, indicating an alternative Wnt-activating mechanism.
Uncharacterized Mutations
Several members of the TCF family are the downstream effectors of Wnt/␤-catenin signaling, notably TCF7/TCF1, LEF, TCF7L1/TCF3, and TCF7L2/TCF4. Point mutations, deletions, and translocations of TCF7L1 and TCF7L2 have been reported in CRCs (9, 12, 16, 24, 105) . However, the Wnt-activating potential of these mutations has not been fully characterized. Specific TCF4 frameshift mutations found in MSI-CRC cells have been shown to be activating mutations by selective loss of TCF4 isoforms with binding ability to the transcriptional repressor CtBP (16) . On the other hand, genome-wide RNAi screening has identified TCF7L2 as a tumor suppressor in CRC cells (109) . In mouse intestine, Tcf4 deletion results in crypt degeneration, whereas loss of Tcf1 and Tcf3 do not show any apparent defect (117) . Together, these data suggest a functional discrepancy of different TCF members between mouse and human. Further investigation is required to explain the difference and to characterize transcriptional regulation mediated by TCF1, TCF3, and TCF4.
Targeting Wnt Signaling in CRC
APC mutations in CRCs were first discovered in 1991 (59, 87) . Since the late 1990s, there has been growing interest in developing therapeutic agents against the Wnt signaling pathway. However, the development of Wnt inhibitors has only reached a promising start recently, and an effective clinically approved drug is still missing. A variety of therapeutic agents modulating the Wnt pathway have been reported, ranging from small-molecule compounds to antibodies and peptides (Fig. 1) . Below, we summarize selected Wnt inhibitors into four classes according to their specific targets: generic, the Wnt-receptor complex, the ␤-catenin destruction complex, and nuclear/transcription factor complexes (Fig. 2) .
Generic Wnt Inhibitors
There are in fact a few FDA-approved drugs that have been shown to modulate the Wnt pathway. However, these drugs belong to the generic category that target Wnt signaling nonspecifically. NSAIDs such as aspirin, indomethacin, and sulindac inhibit the activity of cyclooxygenase (COX), which is a key enzyme in the arachidonic acid cascade. Several studies have suggested that both NSAIDs and the COX2 inhibitor celecoxib can inhibit Wnt/␤-catenin transcription in CRC cells and prevent polyp formation in patients with FAP and mouse models (7, 13, 23, 41, 46, 96) . The data suggest that controlling COX2-dependent prostaglandin E2 (PGE 2 ) production can potentially have chemopreventive effects in human colon cancer. Vitamins have also been reported to have the potential to reduce cancer risk. For example, Vitamin A (retinoid) has been shown to decrease ␤-catenin protein levels (20, 106) , and Vitamin D (1␣,25-dihydroxyvitamin D3) was also suggested to have therapeutic potential for cancer (3, 49) . Several studies have suggested that vitamins can repress Wnt/␤-catenin signaling at many levels, including competition for nuclear ␤-catenin binding with TCF upon activation of the vitamin nuclear receptors or activation of Wnt inhibitor (Dickkopf, DKK) transcription (88, 89, 101) . Despite the potential benefit of these generic agents in Wnt suppression and cancer therapy, the detailed molecular mechanisms remain to be elucidated.
Wnt-Receptor Complex Inhibitors
Porcupine inhibitors. Porcupine (PORCN) is a membranebound O-acyltransferase (MBOAT) residing in endoplasmic reticulum (ER), which adds the palmitoyl group to Wnt proteins, a critical lipid-modifying step for processing Wnt ligand secretion (2, 14, 53, 108, 121) . In 2009, Chen and colleagues (14) identified a class of small molecules that inhibit Wnt protein production, inhibitors of Wnt production (IWPs) (14) . IWP compounds are believed to act specifically on the Wnt pathway because they failed to suppress Notch-mediated signaling or to block general protein secretion, and they did not affect palmitoylation of Sonic hedgehog, a substrate of another MBOAT member, Hedgehog acyltransferase (14) . A more recent study identified another potent porcupine inhibitor LGK974 that showed 63% tumor regression in mice with no adverse effect in normal Wnt-dependent tissues at the efficacious dose (73) . The data indicate the therapeutic potential of PORCN inhibitors to treat cancers that are exogenous Wnt dependent, such as LKB1 and RNF43 mutations in CRCs (63).
Loss-of-function mutations in the tumor suppressor kinase LKB1 fail to restrain the activity of FZD receptors (55, 75), whereas RNF43 loss fails to remove Wnt receptors from the cell surface (48, 62).
Receptor/ligand interference. Another approach toward Wnt-receptor complex directed therapy is to target specific Wnt ligands or receptors that are found overexpressed in tumors. Therapeutic monoclonal antibodies against Wnt-1 and Wnt-2 have been shown to inhibit Wnt signaling and suppress tumor growth in vivo (110, 124, 126) . These antibodies drive apoptosis in different tumor models, including melanoma, non-small cell lung carcinoma, mesothelioma, sarcoma, breast cancer, and CRC cells (50, 51, 78, 127). Another monoclonal antibody OMP-18R5 (OncoMed Pharmaceuticals/Bayer) has been reported to target the FZD receptors and inhibit tumor growth in patient-derived xenograft mouse models by blocking Wnt ligand engagement (47). This product is currently in phase I clinical trials. On the other hand, a soluble Fc-fusion protein with the cysteine-rich domain of FZD8 (FZD8-CRD-Fc) has also been shown to inhibit autocrine Wnt signaling in vitro and in xenograft models (19) . Mice treated with this soluble receptor exhibited no signs of toxicity after several weeks of treatment, suggesting that pan-Wnt inhibition may be a safe approach for tumor-specific treatment. Finally, the therapeutic potential of secretory Wnt antagonists such as secreted FZDrelated proteins (SFRPs) and Wnt inhibitory protein has been suggested by interrupting binding between Wnt ligands and receptors (11) . SFRP1 protein or SFRP1-derived peptides suppress HCT116 xenograft tumor formation in mice (67) . Similarly, another secretory Wnt inhibitor DKK antagonizes Wnt signaling by disrupting Wnt-induced FZD-LRP6 complex formation (25, 43, 99) . Together, the data suggest that antibody or peptide treatment can be used to block Wnt signaling by targeting Wnt ligand-receptor complexes.
␤-Catenin-Destruction Complex Inhibitors
Dishevelled inhibitors. The ability of DVL to bind to both the Wnt receptors and AXIN indicates its unique role in Wnt signal transduction. DVL binds to the carboxyl terminal end of the FZD receptors through its PDZ domain, a common proteininteraction domain. Small molecule compounds targeting specifically the FZD and DVL-PDZ interaction (NSC668036, FJ9, and 3289 -8625) have been identified to block the signal transduction cascade. These compounds have been shown to inhibit Wnt signaling and suppress tumor cell growth in prostate, colon, and lung cancer cells (35, 45, 102) .
Tankyrase inhibitors. Two small-molecule inhibitors targeting tankyrases [poly(ADP)-ribosylating enzymes] were identified in 2009 that show Wnt-antagonizing effects in colon cancer cells. Chen and colleagues (14) first discovered a group of compounds named inhibitors of Wnt response (IWR), which stabilize AXIN proteins and inhibit Wnt signaling (14) . Treatment of IWR-1 in zebrafish inhibits tailfin regeneration and blocks normal gastrointestinal tissue homeostasis. Further analysis showed that IWR-1 inhibits Wnt/␤-catenin transcriptional activity in DLD-1 human CRC cells, which harbor an inactivating APC mutation. Subsequent studies by Huang and collaborators (53) using a high-throughput screen identified another Wnt inhibitor, XAV939. This study further revealed the cellular targets of both XAV939 and IWR-1, suggesting that they regulate AXIN protein levels by inhibiting tankyrase 1 and tankyrase 2. XAV939 was also demonstrated to inhibit Wnt/␤-catenin signaling in the APC-mutated CRC cell lines SW480 and DLD-1. It was later on reported that RNF146, a RING-domain E3 ubiquitin ligase, directly interacts with tankyrase and mediates tankyrase-dependent AXIN degradation (129) . More recently, a number of new tankyrase inhibitors, JW55, JW67, and JW64, have been reported with the potential to inhibit Wnt signaling and suppress tumor growth in Apc mutant mice (121, 122) . However, further detailed analysis of these inhibitor analogs demonstrated intestinal toxicity, which limits the full potential of the antitumor activity of these drugs (66) . Together, these studies highlight the therapeutic potential of tankyrase inhibitors for APC-mutated cancers. However, safety concern remains to be addressed because of the observation of nontumor-specific Wnt inhibition in preclinical models.
␤-Catenin/TCF Transcription Complex Inhibitors
␤-Catenin/TCF antagonists. Discovery of Wnt inhibitors targeting downstream transcription effectors is of great interest because of the diversity of Wnt pathway mutations identified at different subcellular levels. A high-throughput ELISA screen of ϳ7,000 purified natural compounds has identified 8 compounds that disrupt ␤-catenin/TCF complex formation in a dose-dependent manner, among which PFK115-584 and CGP049090 were the two most effective compounds (70) . However, these compounds were also found to target nonspecifically the ␤-catenin/APC interaction, indicating the unselective pharmacological interference with ␤-catenin complexes. Several other compounds have been reported in individual screens that inhibit Wnt target gene transcription and suppress CRC cell growth by targeting ␤-catenin/TCF interactions (44, 115, 123) . Further investigation of these compounds will be important to validate how selective they are in ␤-catenin/TCF targeting and to evaluate their toxicity and whether they impact on normal homeostatic tissue functions at the effective dose.
Wnt coactivator antagonists. Upon Wnt activation, ␤-catenin recruits the transcriptional coactivator cAMP-response element-binding protein-binding protein (CBP) or its homolog p300 to form a transcriptionally active complex together with other components. In 2004, a small-molecule compound ICG-001 was identified that antagonizes ␤-catenin/ TCF transcription (26) . ICG-001 binds specifically the coactivator CBP but not p300 and inhibits Wnt signaling by disrupting the interaction of CBP and ␤-catenin. Several studies have subsequently demonstrated the ability of ICG-001 to eliminate drug-resistant tumor cells by inducing apoptosis (37, 52, 68, 125) . The promising tumor-suppressive effect and lack of toxicity highlight the therapeutic potential of ICG-001 for cancer treatment. More functional studies of ␤-catenin/CBP antagonists will be important to characterize the drug specificity regarding safety and its potential effect on other CBPdependent signaling pathways.
Therapeutic Efficacy of Wnt Inhibitors in the Clinic
Considering the diversity of Wnt-targeting strategies and the Wnt pathway mutation spectrum, it is important to identify the appropriate agents to treat patients with cancer carrying specific mutations. Understanding where and how the Wnt modulator acts in the pathway will help determine the therapeutic efficacy of a particular agent. A general approach is to match the Wnt inhibitor with the mutation, such that it acts at the same target or equivalent subcellular level (i.e., membranereceptor complex, cytoplasmic-destruction complex, or nuclear-␤-catenin/TCF transcription complex). For instance, PORCN inhibitors function to block Wnt ligand secretion and thus are suitable for treating cancers that are exogenous Wnt dependent. These include tumors carrying mutations acting only at the receptor level, such as RNF43 and LKB1 that are both regulating FZD receptors. On the other hand, mutations acting downstream of the receptors, such as APC truncations, activate the Wnt pathway constitutively in the absence of Wnt ligand and are therefore resistant to PORCN inhibitors. Somatic mutations of RNF43 are reported in over 18% of CRCs, predominantly in MSI tumors, whereas LKB1 mutations are relatively rare, suggesting that PORCN inhibitors can potentially be efficacious in over 18% of CRCs (4, 40) . However, the drug efficacy has to be reevaluated when mutations in more than one Wnt pathway component are detected in the same tumor. For example, hypermutated MSI CRCs harboring simultaneous inactivating mutations of RNF43 and APC will unlikely respond to PORCN inhibitors because of the dominant downstream mutations at APC. DVL inhibitors target FZD and DVL-PDZ interactions and therefore block signal transduction from receptor to cytoplasmic-destruction complex. This implies that most APC-mutated CRCs with mutations downstream of DVL will be resistant to DVL inhibitors. In contrast, tankyrase inhibitors are reported to target specifically APCmutated tumors, which constitute Ͼ80% of CRCs. This would have a high therapeutic value if the toxicity concerns could be resolved. ␤-Catenin/TCF complex antagonists target the furthest downstream effectors, i.e., those involved in transcription, which ideally have the greatest therapeutic potential to treat most CRCs with various upstream mutations. Nevertheless, such targeting approaches may provide little if any selection between tumor and normal tissues, which may well restrain their ability to achieve both efficacy and safety in the clinic. Further investigation is needed to identify the safe therapeutic dosage. In a nutshell, identifying mutation-specific Wnt inhibitors as well as the safe efficacious dose are the two key elements to target the Wnt pathway safely in the clinic.
Challenges of Targeting the Wnt Pathway
Aberrant Wnt signaling has been associated with many types of cancer and other diseases and is therefore an attractive target for therapeutic intervention. Thus far, no approved drugs are available in the clinic for treatment via targeting of the Wnt signaling pathway despite the substantial effort put on therapeutic development of Wnt inhibitors in the past two decades. One major challenge of drugging the Wnt pathway is attributable to its crucial role in normal development and adult tissue homeostasis. Many high-turnover tissues such as gastrointestinal epithelium and hair follicles require Wnt signaling for stem cell maintenance and tissue regeneration. Interference of this pathway will target, not only Wnt-activated cancer cells, but also the normal stem cell populations of Wnt-dependent tissues, resulting in significant toxicity. Caution must be taken when utilizing Wnt inhibitors to identify the optimal safe and efficacious dose.
Another important point to consider when targeting Wnt signaling is the network crosstalk between pathways. Indeed, many studies have demonstrated the capability of Wnt signaling to transactivate other signaling pathways in different cellular contexts. For instance, suppression of Wnt signaling by Notch has been reported in keratinocytes and skin tissues (86, 91) . In adult intestine, Wnt and Notch signaling are important in both intestinal homeostasis and tumorigenesis (33, 118) . Wnt and Notch work synergistically together in the murine intestine to trigger intestinal tumorigenesis particularly in colon, which is unusual in Apc-deficient mouse models but typical in human CRCs (33) . Recent studies show that activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway is required for proliferation of APCdepleted cells (28) . Treatment with the serine/threonine kinase mTOR inhibitor rapamycin will block Wnt-activated tumor growth, whereas normal intestinal homeostasis is unaffected. The data suggest that targeting the mTORC1 pathway would provide therapeutic benefit during the early development of CRC. Crosstalk between the Wnt and Hippo pathway has also been implicated in intestinal homeostasis. The downstream effector YAP was shown to restrict intestinal regeneration and suppress Wnt signaling by blocking Dvl nuclear localization (8) , whereas potential regulation of the ␤-catenin destruction complex by YAP and TAZ has also been suggested (5) . The recent discovery of tankyrase inhibitors as Wnt modulators has further unraveled the role of tankyrase dependent-poly(ADPribosyl)ation to regulate Axin degradation, whereas tankyrase has also been reported to regulate telomerase homeostasis, glucose metabolism, and mitotic spindle formation (69) . Together, the data suggest a complex interaction of Wnt signaling with many other cellular pathways in both cancer and normal tissue homeostasis. Better understanding of the crosstalk will be key to design an effective therapeutic strategy and to explore the potential of combination therapy for targeting multiple pathways.
Although Wnt signaling has been extensively characterized in the past three decades, a number of novel Wnt regulators or mechanisms have only been reported recently. The identification of Lgr5 as an intestinal stem cell marker in 2007 has subsequently uncovered the role of R-spondin and LGR receptors in potentiating Wnt signal strength (6, 17, 42) . Recent studies of Rnf43 and Znrf3 in mouse and zebrafish have further revealed the Wnt negative feedback mechanism via receptor regulation (48, 62). More recently, another Wnt inhibitor Notum has also been demonstrated to deacylate Wnt protein extracellularly, adding yet another level of regulation of the Wnt proteins (57, 128) . At the cytosolic destruction complex level, it is well established that ␤-catenin is degraded via phosphorylation and ubiquitination. However, the fundamental mechanism of Wnt-induced Axin-destruction complex inactivation is still controversial. We have previously redefined the physiological Wnt-activating mechanism by showing that inactivation of ␤-catenin ubiquitination is the principal initial Wnt-activating mechanism, whereas phosphorylation is unaffected (71) . Our data challenged the previous dogma that ␤-catenin phosphorylation is inhibited upon Wnt activation. It is important to note that the choices of cell lines, time points, and experimental strategy are all crucial parameters for mechanistic studies. Given that ␤-catenin is involved in multiple cellular processes including membrane adherens junctions, caution has to be taken when interpreting data generated from whole-cell lysates vs. specific complex pull down. Further investigation is needed to elucidate the complete picture of the Wnt signaling pathway in a time course-and context-dependent manner. Finally, it will be important to study the mechanistic differences involved in the destruction complex between wild-type and Wnt-activated tumor cells (such as APC mutants) for future development of tumor-specific Wnt inhibitors.
Future Prospects
Despite many exciting preclinical studies for drugging the Wnt signaling pathway in cancers and other disease models, only a limited number of agents have recently entered clinical trials. To develop more effective Wnt inhibitors, it is important to answer outstanding questions relating to the mechanisms by which the Wnt pathway functions. A better understanding of the mechanistic difference between physiological and pathological Wnt activation is crucial for identifying tumor-specific therapeutic targets with minimal toxicity to normal tissues. Recent advances in high-throughput sequencing of human cancers have uncovered more novel Wnt pathway mutations, which provide exciting avenues for drug targeting and personalized medicine. Given the wide variety of Wnt inhibitors targeting different subcellular levels, it is important to select the right agents for specific mutations. To date, most preclinical studies rely largely on nonphysiological cancer cell lines or complicated and time-consuming patient-derived xenografts. Recent development of cancer organoids allows us to establish efficient and long-term culture of primary human CRC tissues, which provide attractive physiological disease models for highthroughput drug screening (95) . It is important to note that deregulation of the Wnt pathway is crucial but not sufficient for CRC tumorigenesis. Stepwise accumulation of other oncogene and/or tumor suppressor gene mutations such as KRAS and p53 is required for tumor progression. It remains unclear whether targeting Wnt signaling alone in advanced CRCs will be sufficient for tumor suppression. However, a recent study has demonstrated that Apc restoration can trigger differentiation and restore intestinal homeostasis in established tumors with Kras and p53 mutations using a transgenic mouse model (22) . The data indicate that Wnt activation is absolutely required to sustain tumor growth in advanced CRC and provide compelling evidence that the Wnt signaling pathway can be an effective therapeutic target for treatment of CRC. 
